Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer.
Ontology highlight
ABSTRACT: Treatments for high-grade serous ovarian cancer (HGSOC) are initially effective but most invariably fail. Although they can successfully suppress the bulk of the tumour cell population, residual cancer cells can enter alternative therapy-resistant cell fates highlighted by proliferative arrest. Understanding the nature of these fates and how cells may resume uncontrolled proliferation will lead to the development of new treatments for HGSOC. In this study, we examine the response of HGSOC cells to standard of care cisplatin chemotherapy and to the RNA Polymerase I transcription inhibitor CX-5461/Pidnarulex, two drugs that elicit a potent DNA damage response and growth arrest. Here, we identify that HGSOC cells exposed to these therapies show multiple hallmarks of therapy-induced senescence
SUBMITTER: Cerra C
PROVIDER: S-EPMC12462457 | biostudies-literature | 2025 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA